This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boos, M.
Right arrow Articles by Schmitz, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boos, M.
Right arrow Articles by Schmitz, F.-J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 938-942, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.938-942.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus

Mechthild Boos,1 Susanne Mayer,1 Ansgar Fischer,1 Karl Köhrer,1 Sibylle Scheuring,1 Peter Heisig,2 Jan Verhoef,3 Ad C. Fluit,3 and F.-J. Schmitz1,3,*

Institute for Medical Microbiology and Virology, Heinrich-Heine Universität Düsseldorf, Düsseldorf,1 and Institute of Pharmaceutical Microbiology, University of Bonn, Bonn,2 Germany, and Eijkman-Winkler Institute for Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands3

Received 24 July 2000/Returned for modification 11 September 2000/Accepted 27 November 2000

Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus isolates were exposed to subinhibitory MICs of ciprofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, clinafloxacin, and gemifloxacin during a 10-day period. Subculturing led to resistance development, regardless of the initial potencies of the quinolones. None of the quinolones was associated with a significantly slower rate of resistance development.

* Corresponding author. Mailing address: Institute for Medical Microbiology and Virology, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, Geb. 22.21, 40225 Düsseldorf, Germany. Phone and fax: 0049-2132-72040. E-mail: schmitfj{at}uni-duesseldorf.de.

Antimicrobial Agents and Chemotherapy, March 2001, p. 938-942, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.938-942.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Leonard, S. N., Kaatz, G. W., Rucker, L. R., Rybak, M. J. (2008). Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 62: 1305-1310 [Abstract] [Full Text]  
  • Billal, D. S., Fedorko, D. P., Yan, S. S., Hotomi, M., Fujihara, K., Nelson, N., Yamanaka, N. (2007). In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother 59: 28-34 [Abstract] [Full Text]  
  • Alonso, R., Mateo, E., Galimand, M., Garaizar, J., Courvalin, P., Cisterna, R. (2005). Clonal Spread of Pediatric Isolates of Ciprofloxacin-Resistant, emm Type 6 Streptococcus pyogenes. J. Clin. Microbiol. 43: 2492-2493 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Kim, M.-J., Yun, H.-J., Kang, J.-W., Kim, S., Kwak, J.-H., Choi, E.-C. (2003). In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother 51: 1011-1016 [Abstract] [Full Text]  
  • Jones, H. E., Brenwald, N. P., Owen, K. A., Gill, M. J. (2003). A multidrug efflux phenotype mutant of Streptococcus pyogenes. J Antimicrob Chemother 51: 707-710 [Abstract] [Full Text]  
  • Schmitz, F.-J., Schwarz, S., Milatovic, D., Verhoef, J., Fluit, A. C. (2002). In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 50: 145-148 [Full Text]  
  • Reinert, R. R., Al-Lahham, A., Lutticken, R., Boos, M., Schmitz, F.-J. (2002). Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. J Antimicrob Chemother 49: 1015-1018 [Abstract] [Full Text]  
  • Schmitz, F.-J., Petridou, J., Jagusch, H., Astfalk, N., Scheuring, S., Schwarz, S. (2002). Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin. J Antimicrob Chemother 49: 611-617 [Abstract] [Full Text]  
  • Schmitz, F.-J., Milatovic, D., Boos, M., Mayer, S., Fluit, A. C. (2002). In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 49: 698-701 [Full Text]  
  • Schmitz, F.-J., Boos, M., Mayer, S., Kohrer, K., Scheuring, S., C. Fluit, A. (2002). In Vitro Activities of Novel Des-Fluoro(6) Quinolone BMS-284756 against Mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus Selected with Different Quinolones. Antimicrob. Agents Chemother. 46: 934-935 [Full Text]  
  • Schmitz, F.-J., Boos, M., Jagusch, H., Mayer, S., Fluit, A. C., Hafner, D. (2001). Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae. J Antimicrob Chemother 48: 588-590 [Full Text]  
  • Linder, J. A., Stafford, R. S. (2001). Antibiotic Treatment of Adults With Sore Throat by Community Primary Care Physicians: A National Survey, 1989-1999. JAMA 286: 1181-1186 [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2001). Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48: 365-374 [Abstract] [Full Text]  
  • Schmitz, F.-J., Boos, M., Mayer, S., Hafner, D., Jagusch, H., Verhoef, J., Fluit, A. C. (2001). Propensity of Fluoroquinolones with Different Moieties at Position 8 to Cause Resistance Development in Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 2666-2667 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»